Promising Phase III Results Give Hope to Patients with Myelodysplastic Syndromes
Yale Cancer Center/Smilow Cancer HospitalBased on the results from this phase III trial, Yale Cancer Center expert Dr. Amer Zeidan says imetelstat, a first-in-class telomerase inhibitor, leads to durable red blood cell transfusion independence and a significant improvement in anemia in heavily transfused lower risk MDS patients.